Literature DB >> 1671815

Non-adrenergic binding sites for the "alpha 2-antagonist" [3H]idazoxan in the rabbit urethral smooth muscle. Pharmacological and biochemical characterization.

F Yablonsky1, J P Dausse.   

Abstract

In the present study, pharmacological and biochemical binding characteristics of [3H]idazoxan, an originally thought alpha 2-adrenoceptor antagonist, have been determined in smooth muscle of rabbit urethra. It is shown that [3H]idazoxan labels with high affinity non-adrenergic binding sites. Specific binding of [3H]idazoxan is inhibited by compounds possessing an imidazoline or a guanidinium moiety whereas phenylethanolamines and classical alpha 2-antagonists are ineffective competitors which suggests an imidazoline-preferring binding site. However, imidazolidines such as clonidine and paminoclonidine are poorly effective, which differs considerably from pharmacological characteristics of imidazoline binding sites previously reported in the central nervous system. In addition, it is shown that K+ and Mn2+ inhibit [3H]idazoxan binding in a competitive and non-competitive manner, respectively. Other cations such as Na+, Li+ and Mg2+ have no significant effect. It is shown that K+ accelerates the dissociation of [3H]idazoxan binding while Mn2+ does not produce any modification. These results suggest that K+ may bind to an allosteric site, while Mn2+ may bind with a membrane component susceptible to alter [3H]idazoxan binding sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671815     DOI: 10.1016/0006-2952(91)90069-h

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery.

Authors:  G J Molderings; F Hentrich; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

2.  Inhibitory presynaptic imidazoline receptors on sympathetic nerves in the rabbit aorta differ from I1- and I2-imidazoline binding sites.

Authors:  G J Molderings; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

3.  Antagonism of levcromakalim by imidazoline- and guanidine-derivatives in rat portal vein: involvement of the delayed rectifier.

Authors:  T Ibbotson; G Edwards; A H Weston
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

4.  Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.

Authors:  N J Mallard; A L Hudson; D J Nutt
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

5.  [3H]idazoxan binding to bovine adrenal medullary membranes: identification and pharmacological characterization of I2-imidazoline sites.

Authors:  G J Molderings; L Kundt; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

6.  Binding of [3H]clonidine to I1-imidazoline sites in bovine adrenal medullary membranes.

Authors:  G J Molderings; D Moura; K Fink; H Bönisch; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.